Almirall and Forest complete Phase III trials of Aclidinium in COPD « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Almirall and Forest complete Phase III trials of Aclidinium in COPD

Posted on July 7, 2008 by crimsoncanary

Almirall and Forest have announced that Phase III trials of Aclidinium in COPD are now complete

Filed under: Uncategorized | Tagged: Almirall, antagonist, COPD, Forest, M3, Muscarinic M3, phase III

« EU approves Relistor for Opioid-Induced Constipation In Advanced Illness Patients Movetis Vasopressin 2 antagonist M0002 enters Phase IIb trials for cirrhotic ascites »

Leave a Reply